SEC Company Response from SciSparc Ltd. (SPRC) (CIK 0001611746) (SPRC) — Mar 20, 2017

SciSparc Ltd. (SPRC) (CIK 0001611746)
Date: March 20, 2017 · CIK: 0001611746 · Accession: 0001213900-17-002597

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-214458

Date

March 20, 2017

Author

Hugh Regan

Form

CORRESP

Company

SciSparc Ltd. (SPRC) (CIK 0001611746)

Letter

Re: THERAPIX BIOSCIENCES LTD.

Laidlaw & Company (UK) Ltd.

March 20, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

Registration Statement on Form F-1 (Registration No. 333-214458)

Concurrence in Acceleration Request

Ladies and Gentlemen:

Laidlaw & Company (UK) Ltd. (“Laidlaw”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Therapix Biosciences Ltd. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on March 21, 2017 pursuant to Rule 461 under the Securities Act. Laidlaw affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
Laidlaw & Company (UK) Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Laidlaw & Company (UK) Ltd.

March 20, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

    Re:
    THERAPIX BIOSCIENCES LTD.

    Registration Statement on Form F-1 (Registration No.
    333-214458)

    Concurrence in Acceleration Request

Ladies and Gentlemen:

Laidlaw & Company
(UK) Ltd. (“Laidlaw”), as representative of the underwriters for the referenced offering, hereby concurs in
the request by Therapix Biosciences Ltd. that the effective date of the above-referenced registration statement be accelerated
to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on March 21, 2017 pursuant to Rule 461 under the Securities
Act. Laidlaw affirms that it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    Laidlaw & Company (UK) Ltd.

    By:
    /s/ Hugh Regan

    Name: Hugh
    Regan
 Title: Executive Director

SecProbe.io